JOHNSON & JOHNSON | 2013 | FY | 3

 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2013
 
2012
 
2011
 
2013
 
2012
 
2011
United States
 
$
31,910

 
29,830

 
28,908

 
$
35,880

 
35,115

 
23,529

Europe
 
18,599

 
16,945

 
17,129

 
24,868

 
25,261

 
19,056

Western Hemisphere excluding U.S. 
 
7,421

 
7,207

 
6,418

 
3,281

 
3,636

 
3,517

Asia-Pacific, Africa
 
13,382

 
13,242

 
12,575

 
2,434

 
2,362

 
2,163

Segments total
 
71,312

 
67,224

 
65,030

 
66,463

 
66,374

 
48,265

General corporate
 
 
 
 
 
 
 
992

 
899

 
750

Other non long-lived assets
 
 
 
 
 
 
 
65,228

 
54,074

 
64,629

Worldwide total
 
$
71,312

 
67,224

 
65,030

 
$
132,683

 
121,347

 
113,644

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2013, 2012 and 2011, the Company did not have a customer that represented 10% of total revenues.
(1) 
Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.
(2) 
General corporate includes cash and marketable securities.
(3) 
Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Diagnostics and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $251 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $98 million of income related to other adjustments comprised of $55 million and $43 million in the Consumer and Pharmaceutical segments, respectively.
(4) 
Includes $1,218 million of net litigation expense comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.
(5) 
Includes $3,310 million of net litigation expense comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.
(6) 
Long-lived assets include property, plant and equipment, net for 2013, 2012 and 2011 of $16,710, $16,097 and $14,739, respectively, and intangible assets and goodwill, net for 2013, 2012 and 2011 of $50,745, $51,176 and $34,276, respectively.

us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock